1. Generics Bulletin
  2. >>Products
  3. >>Generics

Azithromycin Leads Off UK Rises In January

Pricewatch UK – January 2024

 
• By Dave Wallace

Azithromycin topped our rundown of the steepest UK generic trade price rises in January 2024, based on figures from WaveData.

Price Watch UK
• Source: Alamy

January 2024 may have been a slightly more subdued month for UK generic price rises compared to the final month of last year – which saw riluzole prices spike heavily amid shortages (Also see "Riluzole Prices Skyrocket As UK Shortages Bite" - Generics Bulletin, 11 January, 2024.) – but there were still plenty of significant movements, according to the latest figures from WaveData.

Based on trade prices to UK independent pharmacists, WaveData reported that the average price of azithromycin 250mg tablets in six-count

More from Generics

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

More from Market Intelligence